Blocking the interaction between the NF-κB-regulated anti-apoptotic protein GADD45b and the JNK kinase MKK7 has been suggested for treating multiple myeloma, leading to the development of the DTP3 peptide, which can kill cancerous cells without affecting normal cells [39]. This evidence concerns the gene MAP2K7 and plasma cell myeloma.